# Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis

> **NCT00096915** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 110 (actual)

## Conditions studied

- Kidney Disease
- Chronic Kidney Disease

## Interventions

- **DRUG:** Darbepoetin Alfa

## Key facts

- **NCT ID:** NCT00096915
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2009-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096915, "Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00096915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*